Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07072234 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

A Phase 1 study of Clear Cell Carcinoma and Phase 1, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07072234: Recruiting Phase 1 study of Clear Cell Carcinoma and Phase 1, sponsored by M.D. Anderson Cancer Center.

NCT07072234 is a Phase 1 study of Clear Cell Carcinoma and Phase 1 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 268-participant average among 3 other Clear Cell Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07072234, a Phase 1 study of Clear Cell Carcinoma and Phase 1, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTACAE) Version (v) 5.0

Conditions Studied

Clear Cell Carcinoma Phase 1 Growth Factor

Interventions

  • DRUG Fludarabine
  • DRUG Dexamethasone
  • DRUG Lymphodepleting chemotherapy
  • DRUG Cyclophosphamate
  • DRUG TGFBR-2 KO CD70 CAR NK

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-09-25
Est. Completion 2030-02-01
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT07072234 shows while recruiting

NCT07072234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 268-participant average among 3 other Clear Cell Carcinoma trials with a reported enrollment target (89% lower).

The record links to 3 conditions, with Clear Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT07072234 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07072234 about?

NCT07072234 is a clinical study titled "Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma". Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

What is the current status of trial NCT07072234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-25. Estimated completion is 2030-02-01.

What conditions does trial NCT07072234 study?

This clinical trial studies the following conditions: Clear Cell Carcinoma, Phase 1, Growth Factor.

What interventions are being tested in trial NCT07072234?

The interventions under investigation include: Fludarabine (DRUG), Dexamethasone (DRUG), Lymphodepleting chemotherapy (DRUG), Cyclophosphamate (DRUG), TGFBR-2 KO CD70 CAR NK (DRUG).

Who is sponsoring clinical trial NCT07072234?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07072234 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07072234

Source: ClinicalTrials.gov NCT07072234, the US trial registry maintained by the National Library of Medicine. NCT07072234 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.